Clinical trial

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852

Study summary

ClinicalTrials.gov

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention BDC-3042 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cemiplimab Normalized identity: cemiplimab View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2023-10-11

PhasePHASE1

Conditions

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Clear Cell Renal Cell Carcinomaverified · MONDO: clear cell renal carcinoma

Ovarian Cancerverified · MONDO: ovarian cancer

Head and Neck Cancerverified · MONDO: head and neck cancer

Colorectal Cancerverified · MONDO: colorectal cancer

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Melanomaverified · MONDO: melanoma

Interventions

BDC-3042DRUG

CemiplimabDRUG · verified · RxNorm: cemiplimab

Sponsors & collaborators

Bolt Biotherapeutics, Inc.lead sponsor

Regeneron Pharmaceuticalscollaborator

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 San AntonioTexas, United States1 AustinTexas, United States1 Palo AltoCalifornia, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06052852 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.